Stock URGN UROGEN PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Delayed Nasdaq
Other stock markets
 15:46:26 2024-06-21 EDT 		5-day change 1st Jan Change
16.36 USD +5.75% Intraday chart for UroGen Pharma Ltd. -14.64% +9.27%
06-18 Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials MT
06-14 Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials
MT
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
BU
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
AQ
Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating
MT
Ladenburg Thalmann Raises Price Target on UroGen Pharma to $53.50 From $48, Maintains Buy Rating
MT
HC Wainwright Adjusts Price Target on UroGen Pharma to $60 From $54, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT
Top Midday Gainers
MT
UroGen Pharma Shares Surge After 'Unprecedented' Results on Bladder Cancer Therapy Trial
MT
Transcript : UroGen Pharma Ltd. - Special Call
UroGen Pharma Ltd. Announces Positive Secondary Endpoint Duration of Response (?Dor?) Data from the Phase 3 ENVISION
CI
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
BU
Transcript : UroGen Pharma Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
BU
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
BU
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
BU
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
CI
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. URGN Stock
  4. News UroGen Pharma Ltd.